Yellin A, Hill L R, Benfield J R
J Thorac Cardiovasc Surg. 1986 May;91(5):674-83.
Of 1,450 patients with upper airway cancers, 189 (13%) had additional cancers. There were 60 cases in which lung cancer occurred after upper airway cancer and a single case in which it preceded upper airway cancer. The occurrence of upper airway plus lung cancer in 61 patients was referred to as multiple airway cancers. The overall incidence of multiple airway cancers was 4.1%, or 1:112 patient-years at risk. The highest incidence of lung cancer was 1:70 patient-years, and this was associated with laryngeal cancer. The mean diagnostic interval between upper airway and lung cancers was 6.1 (0 to 23) years, including nine cases (14.8%) in which the two were synchronous. Triple endoscopy revealed occult lung cancer only once. The use of mediastinoscopy (n = 9) and other surgical staging procedures (n = 9) was limited, because previous treatment of upper airway cancers made such procedures impractical and also because interpretation of findings would have been difficult. Past reports have indicated that lung cancer in association with upper airway cancer is almost invariably squamous cell and almost always develops in men. By contrast, among our 61 patients, the incidence of adenocarcinomas was 24%, and 16 patients or 26% were women. Among patients whose records could be evaluated in this regard, symptoms were present in 27 of 55 (49%); the cancers were in Stage III at presentation in 51%. Outcome was related to symptomatology and to lung cancer stage. The median survivals for symptomatic and asymptomatic patients were 6 and 25 months, respectively (p less than 0.001); the median survivals for patients with Stage I, II, and III lesions were 26, 9, and 6 months, respectively (p less than 0.05). Post-thoracotomy management after surgical-radiation therapy of upper airway cancers (n = 22) was inordinately challenging because of preexisting impairment of the upper airways. We have reached the following conclusions: Patients with upper airway cancer are at high risk for lung cancer of all cell types. When multiple airway cancers occur together, the prognosis is poor; nonetheless, cure of each cancer can be achieved if it is completely and adequately treated. When multiple airway cancers occur synchronously, the more life-threatening cancer should be treated first. When the option exists, the lung cancer should be treated before the upper airway cancer to avoid the impact of previous irradiation and/or surgical treatment of the upper airway cancer upon post-thoracotomy management.
在1450例上呼吸道癌患者中,189例(13%)还患有其他癌症。其中60例肺癌发生在上呼吸道癌之后,1例肺癌发生在上呼吸道癌之前。61例患者同时发生上呼吸道癌和肺癌被称为多气道癌。多气道癌的总体发病率为4.1%,即每112人年有1例发病风险。肺癌的最高发病率为每70人年1例,且与喉癌相关。上呼吸道癌和肺癌的平均诊断间隔为6.1(0至23)年,其中9例(14.8%)两者为同步发生。三联内镜检查仅一次发现隐匿性肺癌。纵隔镜检查(n = 9)和其他手术分期程序(n = 9)的应用有限,因为上呼吸道癌的既往治疗使这些程序不切实际,而且对检查结果的解读也会很困难。既往报告表明,与上呼吸道癌相关的肺癌几乎均为鳞状细胞癌,且几乎都发生在男性患者中。相比之下,在我们的61例患者中,腺癌的发病率为24%,16例(26%)为女性。在这方面记录可评估的患者中,55例中有27例(49%)有症状;初诊时癌症处于Ⅲ期的患者占51%。预后与症状表现和肺癌分期相关。有症状和无症状患者的中位生存期分别为6个月和25个月(p < 0.001);Ⅰ期、Ⅱ期和Ⅲ期病变患者的中位生存期分别为26个月、9个月和6个月(p < 0.05)。由于上呼吸道已存在功能损害,对上呼吸道癌进行手术放疗后(n = 22)的开胸后管理极具挑战性。我们得出了以下结论:上呼吸道癌患者患所有细胞类型肺癌的风险都很高。当多气道癌同时发生时,预后较差;尽管如此,如果每种癌症都得到彻底和充分的治疗,仍可实现治愈。当多气道癌同步发生时,应先治疗威胁生命更大的癌症。如果有选择,应先治疗肺癌,再治疗上呼吸道癌,以避免上呼吸道癌既往的放疗和/或手术治疗对开胸后管理产生影响。